P&G Hygiene and Healthcare faces margin pressure as 1QFY27 earnings miss estimates

Investment View and Valuation

Motilal Oswal Financial Services Limited (MOFSL) maintained its Neutral recommendation on P&G Hygiene and Healthcare following a weak 1QFY27 performance. MOFSL revised its target price to Rs 9,500, based on 35 times March 2028E EPS. Against the report’s CMP of Rs 8,599, this implies approximately 10 per cent upside.

The report highlights substantial quarterly volatility, subdued revenue growth and margin pressure. The stock had corrected by about 35 per cent over the preceding year.

1QFY27 Performance

P&G Hygiene and Healthcare reported 1QFY27 revenue of Rs 891.5 crore, down 5 per cent year-on-year and materially below MOFSL’s estimate of about Rs 1,000 crore. The comparison base was broadly flat, with revenue growth of 0.6 per cent in 1QFY26.

Margin and Cost Pressures

Gross margin declined by 630 basis points year-on-year and 470 basis points quarter-on-quarter to 57.3 per cent, versus MOFSL’s estimate of 63.5 per cent. The contraction reflected commodity-cost inflation amid geopolitical uncertainty.

Employee cost increased 12 per cent year-on-year, while advertising and promotion spending rose 21 per cent. Other expenses declined 4 per cent. Despite raw-material inflation, the company continued to invest in product innovation, advertising and brand building.

EBITDA declined 36 per cent year-on-year to Rs 170.1 crore, while EBITDA margin contracted 930 basis points year-on-year and 410 basis points sequentially to 19.1 per cent. PBT declined 36 per cent and adjusted PAT declined 34 per cent year-on-year to about Rs 126 crore.

Operating Environment and Growth Outlook

Management told analysts that the operating environment is likely to remain challenging as macro inflation keeps consumers value-conscious. It also highlighted soft demand trends in both rural and urban markets.

MOFSL expects profitability to remain exposed to high input costs and ongoing brand investments. However, it models EBITDA margins of 26.0-26.5 per cent in FY27E and FY28E.

Long-Term Positives

• Feminine hygiene growth: The segment represents 65-68 per cent of sales and offers scope for market-share gains through strategic initiatives and strengthened competitive advantages.
• Premiumisation: Long-term premiumisation in feminine hygiene could support margin expansion.
• Innovation-led acquisition: The company remains focused on acquiring customers through innovation across its essentials and healthcare portfolio.

MOFSL expects the penetration opportunity to progress at a stable pace despite the scope for user additions and sees no medium-term upside trigger.

Earnings Estimates and Forecasts

Following the weak quarter, MOFSL cut its FY27E and FY28E EPS estimates by 5-6 per cent. Its revised forecasts imply FY26-FY28E revenue, EBITDA and PAT CAGR of 6 per cent, 5 per cent and 5 per cent, respectively.

Key Concerns Behind the Neutral View

• Weak demand across rural and urban markets.
• Input-cost-led volatility in gross margins.
• Continued investment in advertising, product innovation and brands.
• A growth outlook that MOFSL considers less attractive than that of other consumer names.
• No medium-term upside trigger despite the long-term penetration opportunity in feminine hygiene.

Overall, MOFSL’s Neutral stance reflects the weak 1QFY27 earnings performance, ongoing margin risks and subdued near-term demand, balanced against the company’s long-term feminine-hygiene growth potential and premiumisation opportunity.